1. In silico identification and experimental validation of hits active against KPC-2 β-lactamase
- Author
-
Donatella Tondi, Raphael Klein, Giuseppe Celenza, Ruth Brenk, Laura Cendron, Pierangelo Bellio, Pasquale Linciano, Sofia Papaioannou, and Jesús Blázquez
- Subjects
Genetics and Molecular Biology (all) ,Proteomics ,0301 basic medicine ,Cefotaxime ,Klebsiella pneumoniae ,Pathology and Laboratory Medicine ,Physical Chemistry ,Biochemistry ,Klebsiella Pneumoniae ,Database and Informatics Methods ,Biochemistry, Genetics and Molecular Biology (all) ,Agricultural and Biological Sciences (all) ,Antibiotics ,Klebsiella ,Catalytic Domain ,Medicine and Health Sciences ,polycyclic compounds ,Drug Interactions ,Crystallography ,Multidisciplinary ,biology ,Antimicrobials ,Organic Compounds ,Proteomic Databases ,Chemistry ,Physics ,Drugs ,Sulbactam ,Condensed Matter Physics ,Bacterial Pathogens ,Medical Microbiology ,Physical Sciences ,Crystal Structure ,Medicine ,Pathogens ,beta-Lactamase Inhibitors ,Research Article ,medicine.drug ,Science ,In silico ,030106 microbiology ,Sulfonamide ,Research and Analysis Methods ,Microbiology ,Meropenem ,Tazobactam ,beta-Lactamases ,03 medical and health sciences ,Bacterial Proteins ,Microbial Control ,Clavulanic acid ,medicine ,Solid State Physics ,Microbial Pathogens ,Pharmacology ,Ligand efficiency ,Chemical Bonding ,Bacteria ,Organic Chemistry ,Chemical Compounds ,Organisms ,Biology and Life Sciences ,Hydrogen Bonding ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,bacterial infections and mycoses ,Amides ,Biological Databases ,030104 developmental biology - Abstract
Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad substrate spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. Moreover, strains harboring KPC-type β-lactamases are often reported as resistant to available β-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identification of novel non β-lactam KPC-2 inhibitors is strongly necessary to maintain treatment options. This study explored novel, non-covalent inhibitors active against KPC-2, as putative hit candidates. We performed a structure-based in silico screening of commercially available compounds for non-β-lactam KPC-2 inhibitors. Thirty-two commercially available high-scoring, fragment-like hits were selected for in vitro validation and their activity and mechanism of action vs the target was experimentally evaluated using recombinant KPC-2. N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluorobenzamide (11a), in light of its ligand efficiency (LE = 0.28 kcal/mol/non-hydrogen atom) and chemistry, was selected as hit to be directed to chemical optimization to improve potency vs the enzyme and explore structural requirement for inhibition in KPC-2 binding site. Further, the compounds were evaluated against clinical strains overexpressing KPC-2 and the most promising compound reduced the MIC of the β-lactam antibiotic meropenem by four-fold. publishedVersion
- Published
- 2018